| Methods |
Randomised
Controlled
Trial
Double‐blind
Parallel‐group
Placebo‐ controlled
Single centre,
ITT analysis |
| Participants |
Country: Italy
Mean age:65
% Female:56
Mean disease duration: NR
Duration:60 days
Number randomised:34
[40 jts: HA 20, PL 20]
Inclusion:
gonarthrosis
pain with clinical signs, e.g. limitation of joint function and of unaided walking
Exclusion:
NR |
| Interventions |
Hyalgan (20mg/2ml)
3 weekly injections
Placebo: phosphate buffer
2 ml 3 weekly injections
Concurrent therapy:
not reported |
| Outcomes |
spontaneous pain intensity VAS ‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐
pain on touch
pain under load
pain while walking (1=none,
2=mild,3=moder‐
ate,4=severe,5=
very severe) |
| Notes |
Jadad's:3/5
R‐1,B‐1,W‐1
6 pts had bilateral disease each knee ran‐
domised |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment (selection bias) |
Unclear risk |
B ‐ Unclear |
